文献类型：期刊文献

英文题名：Research Progress on the Association Between GLP-1 Receptor Agonists and Cardiomyopathy

作者：Yang, Xiao[1];Li, Xinghui[2]

第一作者：杨鑫

通信作者：Li, XH[1]

机构：[1]Gansu Univ Tradit Chinese Med, Clin Med Coll 1, Lanzhou 730000, Gansu, Peoples R China;[2]Gansu Prov Peoples Hosp, Dept Cardiol, Lanzhou 730000, Gansu, Peoples R China

第一机构：甘肃中医药大学

通信机构：[1]corresponding author), Gansu Prov Peoples Hosp, Dept Cardiol, Lanzhou 730000, Gansu, Peoples R China.

年份：2025

卷号：26

期号：8

外文期刊名：REVIEWS IN CARDIOVASCULAR MEDICINE

收录：;Scopus(收录号：2-s2.0-105016902870);WOS:【SCI-EXPANDED(收录号:WOS:001567945800002)】；

基金：Not applicable.

语种：英文

外文关键词：GLP-1RAs; cardiomyopathy; T2DM

摘要：Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are a promising new class of drugs, whose clinical potential has recently been explored. Various preclinical studies and clinical trials initially demonstrated the efficacy of GLP-1RAs in treating type 2 diabetes mellitus (T2DM). However, long-term clinical practice has revealed that GLP-1RAs also exhibit significant efficacy and preventive effects in cardiovascular diseases. These effects are mediated through multiple gene pathways; thus, these drugs have shown substantial potential for further development in different clinical contexts. Cardiomyopathy, which constitutes a significant proportion of cardiovascular-related diseases, is increasingly prevalent, with its incidence rising annually. Thus, following the recent surge in research on cardiomyopathy, this review aims to summarize the latest findings regarding the association between GLP-1RAs and cardiomyopathy. This review begins with an introduction to GLP-1RAs, discussing their specific mechanisms of action. This article then addresses the pathogenesis, progression, and mechanisms of cardiomyopathy. Subsequently, a detailed analysis of the relationship between GLP-1RAs and cardiomyopathy is conducted. Finally, this review summarizes and discusses the latest literature on the impact of GLP-1RAs on the risk of various types of cardiomyopathy, as well as the potential underlying biological mechanisms, to provide clinical guidance on the use of GLP-1RAs in the treatment of cardiomyopathy.